Showing 2791-2800 of 10820 results for "".
Finding the Right Medication for the Right Patient with Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37180/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, explains how to select the optimal therapeutic option for each different atopic dermatitis patient.Rosacea: New and Old Medications, Isotretinoin, and Flushing
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/rosacea-new-and-old-medications-isotretinoin-and-flushing/54654/Hilary Baldwin, MD, discusses key takeaways from the “Acne and Rosacea: Update 2026” session at Maui Derm Hawaii 2026.Food Allergies and Atopic Dermatitis in the Pediatric Population
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/food-allergies-and-atopic-dermatitis-in-the-pediatric-population/37175/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses potential links between food allergies and pediatric atopic dermatitis, and how to address them.Unmet Needs in Atopic Dermatitis Management
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/unmet-needs-in-atopic-dermatitis-management/37145/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, says the most pressing unmet needs in atopic dermatitis management today involve the targets of therapyEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urNew Devices and Adaptogens
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39741/Jacqueline Watchmaker, MD, explores the intersection of medical devices and adaptogenic therapies in skincare. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.The Battle of Biostimulators: PLLA vs Hyperdilute CaHA
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/the-battle-of-biostimulators-plla-vs-hyperdilute-caha/39250/Modern Aesthetics executive editor Kay Durairaj, MD, FACS, hosts a workshop describing the differences between two dermal filler options, and how she utilizes both in her practice. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank oIncreased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitis